|
Volumn 175, Issue 8, 2006, Pages 874-875
|
Triptan migraine treatments and antidepressants: Risk of serotonin syndrome
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
3,4 METHYLENEDIOXYMETHAMPHETAMINE;
AMPHETAMINE;
ANALGESIC AGENT;
ANTIBIOTIC AGENT;
ANTICONVULSIVE AGENT;
ANTIDEPRESSANT AGENT;
ANTIEMETIC AGENT;
ANTIOBESITY AGENT;
ANTITUSSIVE AGENT;
CITALOPRAM;
CLORGYLINE;
COCAINE;
DEXTROMETHORPHAN;
ESCITALOPRAM;
FENTANYL;
HERBACEOUS AGENT;
LEVODOPA;
LINEZOLID;
METOCLOPRAMIDE;
ONDANSETRON;
PENTAZOCINE;
PETHIDINE;
RITONAVIR;
SEROTONIN UPTAKE INHIBITOR;
SIBUTRAMINE;
TRAMADOL;
TRIPTAN DERIVATIVE;
UNINDEXED DRUG;
VALPROIC ACID;
VENLAFAXINE;
TRYPTAMINE DERIVATIVE;
ARTICLE;
AUTONOMIC NEUROPATHY;
CATABOLISM;
CLINICAL FEATURE;
DIAGNOSTIC TEST;
DRUG MECHANISM;
FOOD AND DRUG ADMINISTRATION;
HOSPITAL ADMISSION;
HUMAN;
MENTAL DEFICIENCY;
MENTAL HEALTH;
MIGRAINE;
NEUROMUSCULAR DISEASE;
PATHOPHYSIOLOGY;
PATIENT MONITORING;
SEROTONIN RELEASE;
SEROTONIN SYNDROME;
CHEMICALLY INDUCED DISORDER;
DRUG INTERACTION;
ANTIDEPRESSIVE AGENTS;
DRUG INTERACTIONS;
HUMANS;
MIGRAINE DISORDERS;
SEROTONIN SYNDROME;
TRYPTAMINES;
|
EID: 33750110000
PISSN: 08203946
EISSN: 14882329
Source Type: Journal
DOI: 10.1503/cmaj.061217 Document Type: Article |
Times cited : (19)
|
References (5)
|